NO323984B1 - Anvendelse av paratyroidhormon for fremstilling av et preparat for a redusere benfraktur - Google Patents

Anvendelse av paratyroidhormon for fremstilling av et preparat for a redusere benfraktur Download PDF

Info

Publication number: NO323984B1
Authority: NO; Norway
Prior art keywords: bone; pth; months; rhpth; cortical
Prior art date: 1998-08-19

Application number

NO20005947A

Other languages

English (en)

Norwegian (no)

Other versions

NO20005947D0 (no

NO20005947L (no

Inventor

Janet Mary Hock

Gregory A Gaich

Willard H Dere

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-19

Filing date

2000-11-24

Publication date

2007-07-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO323984(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-11-24 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2000-11-24 Publication of NO20005947D0 publication Critical patent/NO20005947D0/no

2000-11-24 Publication of NO20005947L publication Critical patent/NO20005947L/no

2007-07-30 Publication of NO323984B1 publication Critical patent/NO323984B1/no

Links

102000003982 Parathyroid hormone Human genes 0.000 title claims description 190
108090000445 Parathyroid hormone Proteins 0.000 title claims description 190
239000000199 parathyroid hormone Substances 0.000 title claims description 190
229960001319 parathyroid hormone Drugs 0.000 title claims description 182
208000010392 Bone Fractures Diseases 0.000 title claims description 47
239000000203 mixture Substances 0.000 title description 13
238000002360 preparation method Methods 0.000 title description 3
208000001132 Osteoporosis Diseases 0.000 claims description 29
239000011575 calcium Substances 0.000 claims description 26
229910052791 calcium Inorganic materials 0.000 claims description 26
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 25
239000000463 material Substances 0.000 claims description 25
101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 claims description 16
101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 13
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 12
229930003316 Vitamin D Natural products 0.000 claims description 11
102000058004 human PTH Human genes 0.000 claims description 11
235000019166 vitamin D Nutrition 0.000 claims description 11
239000011710 vitamin D Substances 0.000 claims description 11
150000003710 vitamin D derivatives Chemical class 0.000 claims description 11
229940046008 vitamin d Drugs 0.000 claims description 11
229940079593 drug Drugs 0.000 claims description 10
239000003795 chemical substances by application Substances 0.000 claims description 8
230000000123 anti-resoprtive effect Effects 0.000 claims description 6
238000010254 subcutaneous injection Methods 0.000 claims description 5
239000007929 subcutaneous injection Substances 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 4
239000005022 packaging material Substances 0.000 claims description 4
125000003275 alpha amino acid group Chemical group 0.000 claims 1
210000000988 bone and bone Anatomy 0.000 description 261
230000001054 cortical effect Effects 0.000 description 79
206010017076 Fracture Diseases 0.000 description 69
238000011282 treatment Methods 0.000 description 65
230000000694 effects Effects 0.000 description 31
230000009467 reduction Effects 0.000 description 31
210000000689 upper leg Anatomy 0.000 description 28
241000283973 Oryctolagus cuniculus Species 0.000 description 26
206010041569 spinal fracture Diseases 0.000 description 26
229910052500 inorganic mineral Inorganic materials 0.000 description 24
239000011707 mineral Substances 0.000 description 24
230000011164 ossification Effects 0.000 description 22
210000002966 serum Anatomy 0.000 description 22
230000008901 benefit Effects 0.000 description 21
238000000034 method Methods 0.000 description 21
241001465754 Metazoa Species 0.000 description 19
238000007634 remodeling Methods 0.000 description 19
210000001624 hip Anatomy 0.000 description 18
239000000902 placebo Substances 0.000 description 18
229940068196 placebo Drugs 0.000 description 18
210000002414 leg Anatomy 0.000 description 17
238000005259 measurement Methods 0.000 description 17
241000282693 Cercopithecidae Species 0.000 description 16
230000008859 change Effects 0.000 description 15
210000002758 humerus Anatomy 0.000 description 15
208000014674 injury Diseases 0.000 description 15
OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 15
230000008733 trauma Effects 0.000 description 15
210000002436 femur neck Anatomy 0.000 description 14
230000002829 reductive effect Effects 0.000 description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
241000282412 Homo Species 0.000 description 12
239000000243 solution Substances 0.000 description 12
241000288906 Primates Species 0.000 description 11
230000033558 biomineral tissue development Effects 0.000 description 11
230000008416 bone turnover Effects 0.000 description 11
150000001413 amino acids Chemical class 0.000 description 10
230000001195 anabolic effect Effects 0.000 description 10
238000004458 analytical method Methods 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 10
230000037118 bone strength Effects 0.000 description 9
210000004705 lumbosacral region Anatomy 0.000 description 9
238000012360 testing method Methods 0.000 description 9
241000282414 Homo sapiens Species 0.000 description 8
210000003423 ankle Anatomy 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
210000002303 tibia Anatomy 0.000 description 8
230000007306 turnover Effects 0.000 description 8
239000000872 buffer Substances 0.000 description 7
235000019441 ethanol Nutrition 0.000 description 7
229940088597 hormone Drugs 0.000 description 7
239000005556 hormone Substances 0.000 description 7
102000002260 Alkaline Phosphatase Human genes 0.000 description 6
108020004774 Alkaline Phosphatase Proteins 0.000 description 6
108700020797 Parathyroid Hormone-Related Proteins 0.000 description 6
102000043299 Parathyroid hormone-related Human genes 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
230000004913 activation Effects 0.000 description 6
230000009286 beneficial effect Effects 0.000 description 6
229940011871 estrogen Drugs 0.000 description 6
239000000262 estrogen Substances 0.000 description 6
230000006872 improvement Effects 0.000 description 6
230000002485 urinary effect Effects 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
206010065687 Bone loss Diseases 0.000 description 5
241000282567 Macaca fascicularis Species 0.000 description 5
229910019142 PO4 Inorganic materials 0.000 description 5
102100036893 Parathyroid hormone Human genes 0.000 description 5
241000700159 Rattus Species 0.000 description 5
241000283984 Rodentia Species 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
108010049264 Teriparatide Proteins 0.000 description 5
230000037396 body weight Effects 0.000 description 5
210000003275 diaphysis Anatomy 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 5
238000009472 formulation Methods 0.000 description 5
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-methyl-PhOH Natural products CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 5
239000010452 phosphate Substances 0.000 description 5
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
239000003755 preservative agent Substances 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 4
208000000038 Hypoparathyroidism Diseases 0.000 description 4
238000005452 bending Methods 0.000 description 4
230000037182 bone density Effects 0.000 description 4
230000024279 bone resorption Effects 0.000 description 4
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
229910003460 diamond Inorganic materials 0.000 description 4
239000010432 diamond Substances 0.000 description 4
235000005911 diet Nutrition 0.000 description 4
201000010099 disease Diseases 0.000 description 4
230000009977 dual effect Effects 0.000 description 4
210000002683 foot Anatomy 0.000 description 4
239000012634 fragment Substances 0.000 description 4
210000001564 haversian system Anatomy 0.000 description 4
230000035800 maturation Effects 0.000 description 4
230000002335 preservative effect Effects 0.000 description 4
210000000614 rib Anatomy 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
208000006386 Bone Resorption Diseases 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
238000011444 antiresorptive therapy Methods 0.000 description 3
230000001851 biosynthetic effect Effects 0.000 description 3
238000002591 computed tomography Methods 0.000 description 3
210000002808 connective tissue Anatomy 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
230000037213 diet Effects 0.000 description 3
238000009826 distribution Methods 0.000 description 3
238000002657 hormone replacement therapy Methods 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
210000004197 pelvis Anatomy 0.000 description 3
229920005862 polyol Polymers 0.000 description 3
150000003077 polyols Chemical class 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
210000002320 radius Anatomy 0.000 description 3
230000004044 response Effects 0.000 description 3
210000000278 spinal cord Anatomy 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
229940095064 tartrate Drugs 0.000 description 3
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
208000020084 Bone disease Diseases 0.000 description 2
101001135732 Bos taurus Parathyroid hormone Proteins 0.000 description 2
102000055006 Calcitonin Human genes 0.000 description 2
108060001064 Calcitonin Proteins 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
238000000305 Fourier transform infrared microscopy Methods 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
206010023509 Kyphosis Diseases 0.000 description 2
102000006461 Parathyroid Hormone Receptors Human genes 0.000 description 2
108010058828 Parathyroid Hormone Receptors Proteins 0.000 description 2
102100032256 Parathyroid hormone/parathyroid hormone-related peptide receptor Human genes 0.000 description 2
101710180613 Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 description 2
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
229960004015 calcitonin Drugs 0.000 description 2
230000004094 calcium homeostasis Effects 0.000 description 2
229940069978 calcium supplement Drugs 0.000 description 2
238000004422 calculation algorithm Methods 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 2
229940109239 creatinine Drugs 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000000245 forearm Anatomy 0.000 description 2
239000003862 glucocorticoid Substances 0.000 description 2
210000001981 hip bone Anatomy 0.000 description 2
210000003041 ligament Anatomy 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
238000011068 loading method Methods 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
229960002378 oftasceine Drugs 0.000 description 2
230000000399 orthopedic effect Effects 0.000 description 2
230000002611 ovarian Effects 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
238000013001 point bending Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000008439 repair process Effects 0.000 description 2
238000009256 replacement therapy Methods 0.000 description 2
238000005070 sampling Methods 0.000 description 2
230000003068 static effect Effects 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
150000005846 sugar alcohols Chemical class 0.000 description 2
230000009469 supplementation Effects 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
229960005460 teriparatide Drugs 0.000 description 2
210000000115 thoracic cavity Anatomy 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
238000005303 weighing Methods 0.000 description 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
RGCKGOZRHPZPFP-UHFFFAOYSA-N Alizarin Natural products C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
229940122361 Bisphosphonate Drugs 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241000581364 Clinitrachus argentatus Species 0.000 description 1
206010010214 Compression fracture Diseases 0.000 description 1
241000777300 Congiopodidae Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
206010020100 Hip fracture Diseases 0.000 description 1
208000037147 Hypercalcaemia Diseases 0.000 description 1
206010020649 Hyperkeratosis Diseases 0.000 description 1
201000002980 Hyperparathyroidism Diseases 0.000 description 1
206010058359 Hypogonadism Diseases 0.000 description 1
238000004971 IR microspectroscopy Methods 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
206010061291 Mineral deficiency Diseases 0.000 description 1
208000006670 Multiple fractures Diseases 0.000 description 1
241000282339 Mustela Species 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
LOJFGJZQOKTUBR-XAQOOIOESA-N NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 LOJFGJZQOKTUBR-XAQOOIOESA-N 0.000 description 1
108010021717 Nafarelin Proteins 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
102000004067 Osteocalcin Human genes 0.000 description 1
108090000573 Osteocalcin Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010050808 Procollagen Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
230000018199 S phase Effects 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
210000000588 acetabulum Anatomy 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000003957 acoustic microscopy Methods 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
HFVAFDPGUJEFBQ-UHFFFAOYSA-M alizarin red S Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=C(S([O-])(=O)=O)C(O)=C2O HFVAFDPGUJEFBQ-UHFFFAOYSA-M 0.000 description 1
239000003263 anabolic agent Substances 0.000 description 1
229940124325 anabolic agent Drugs 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000000784 arm bone Anatomy 0.000 description 1
206010003230 arteritis Diseases 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
229960001950 benzethonium chloride Drugs 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000003150 biochemical marker Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
150000004663 bisphosphonates Chemical class 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
238000007470 bone biopsy Methods 0.000 description 1
230000018678 bone mineralization Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
150000001896 cresols Chemical class 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000011257 definitive treatment Methods 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000004821 effect on bone Effects 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
210000002082 fibula Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229940091249 fluoride supplement Drugs 0.000 description 1
235000013305 food Nutrition 0.000 description 1
-1 for example Chemical class 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
210000004349 growth plate Anatomy 0.000 description 1
230000035876 healing Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
238000011540 hip replacement Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000000148 hypercalcaemia Effects 0.000 description 1
208000030915 hypercalcemia disease Diseases 0.000 description 1
210000003692 ilium Anatomy 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000003999 initiator Substances 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000005067 joint tissue Anatomy 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
210000001930 leg bone Anatomy 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
229960001078 lithium Drugs 0.000 description 1
208000018769 loss of vision Diseases 0.000 description 1
231100000864 loss of vision Toxicity 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
125000003717 m-cresyl group Chemical group [H]C1=C([H])C(O*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000010198 maturation time Effects 0.000 description 1
230000005226 mechanical processes and functions Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
230000001089 mineralizing effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
FSBTYDWUUWLHBD-UDXTWCDOSA-N nafarelin acetate hydrate Chemical compound O.CC(O)=O.C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 FSBTYDWUUWLHBD-UDXTWCDOSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
235000003170 nutritional factors Nutrition 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
238000009806 oophorectomy Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
230000001009 osteoporotic effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
210000002990 parathyroid gland Anatomy 0.000 description 1
108010073509 parathyroid hormone (1-31) Proteins 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940067107 phenylethyl alcohol Drugs 0.000 description 1
PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
238000013105 post hoc analysis Methods 0.000 description 1
239000000843 powder Substances 0.000 description 1
206010036601 premature menopause Diseases 0.000 description 1
230000002265 prevention Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
238000011552 rat model Methods 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000000682 scanning probe acoustic microscopy Methods 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000003351 stiffener Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
229940086546 synarel Drugs 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
229940034208 thyroxine Drugs 0.000 description 1
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000004393 visual impairment Effects 0.000 description 1
235000005282 vitamin D3 Nutrition 0.000 description 1
239000011647 vitamin D3 Substances 0.000 description 1
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
229940021056 vitamin d3 Drugs 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Orthopedic Medicine & Surgery (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Orthopedics, Nursing, And Contraception (AREA)
Steroid Compounds (AREA)
Materials For Medical Uses (AREA)

NO20005947A 1998-08-19 2000-11-24 Anvendelse av paratyroidhormon for fremstilling av et preparat for a redusere benfraktur NO323984B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US9715198P	1998-08-19	1998-08-19
US9974698P	1998-09-10	1998-09-10
PCT/US1999/018961 WO2000010596A1 (en)	1998-08-19	1999-08-19	Method of increasing bone toughness and stiffness and reducing fractures

Publications (3)

Publication Number	Publication Date
NO20005947D0 NO20005947D0 (no)	2000-11-24
NO20005947L NO20005947L (no)	2000-11-24
NO323984B1 true NO323984B1 (no)	2007-07-30

Family

ID=26792729

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20005947A NO323984B1 (no)	1998-08-19	2000-11-24	Anvendelse av paratyroidhormon for fremstilling av et preparat for a redusere benfraktur
NO20072983A NO20072983L (no)	1998-08-19	2007-06-11	Anvendelse av paratyroidhormon for fremstilling av et medikament for a redusere risiko for frakturer

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20072983A NO20072983L (no)	1998-08-19	2007-06-11	Anvendelse av paratyroidhormon for fremstilling av et medikament for a redusere risiko for frakturer

Country Status (32)

Country	Link
US (2)	US6977077B1 (da)
EP (3)	EP2907522B1 (da)
JP (5)	JP2002523375A (da)
KR (1)	KR100454207B1 (da)
CN (1)	CN1205997C (da)
AR (1)	AR033639A1 (da)
AT (1)	ATE231000T1 (da)
AU (1)	AU746277B2 (da)
BR (1)	BR9909445A (da)
CA (1)	CA2325371C (da)
CO (1)	CO5130020A1 (da)
CY (2)	CY1113343T1 (da)
CZ (1)	CZ301017B6 (da)
DE (2)	DE15152726T1 (da)
DK (4)	DK1059933T3 (da)
DZ (1)	DZ2873A1 (da)
EA (1)	EA003362B1 (da)
ES (4)	ES2549551T3 (da)
HR (1)	HRP20000755A2 (da)
HU (2)	HU230697B1 (da)
ID (1)	ID29039A (da)
IL (2)	IL138829A0 (da)
MY (1)	MY129227A (da)
NO (2)	NO323984B1 (da)
NZ (1)	NZ507056A (da)
PE (1)	PE20001089A1 (da)
PL (1)	PL201688B1 (da)
PT (4)	PT2266598T (da)
TR (1)	TR200003455T2 (da)
TW (1)	TW576747B (da)
UA (1)	UA72205C2 (da)
WO (1)	WO2000010596A1 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6770623B1 (en) *	1997-12-09	2004-08-03	Eli Lilly And Company	Stabilized teriparatide solutions
US20040033950A1 (en) *	2000-09-26	2004-02-19	Hock Janet M.	Method of increasing bone toughness and stiffness and reducing fractures
DZ2873A1 (fr) *	1998-08-19	2003-12-15	Lilly Co Eli	Procédé pour augmenter la dureté et la rigidité osseuse.
WO2001022093A1 (en) *	1999-09-20	2001-03-29	Eli Lilly And Company	Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en)	2001-12-18	2007-07-24	Universitat Zurich	Growth factor modified protein matrices for tissue engineering
WO2003059291A2 (en) *	2002-01-10	2003-07-24	Osteotrophin Llc	Treatment of bone disorders with skeletal anabolic drugs
US8088734B2 (en)	2003-01-21	2012-01-03	Unigene Laboratories Inc.	Oral delivery of peptides
WO2005027915A1 (en) *	2003-09-19	2005-03-31	Pfizer Products Inc.	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
US20060189533A1 (en) *	2004-05-10	2006-08-24	Nastech Pharmaceutical Company Inc.	Stable pharmaceutical dosage forms of teriparatide
US20060052305A1 (en) *	2004-05-10	2006-03-09	Nastech Pharmaceutical Company Inc.	Method of treating osteoporosis using intranasal parathyroid hormone
US20060127320A1 (en) *	2004-05-10	2006-06-15	Nastech Pharmaceutical Company Inc.	Method of delivering parathyroid hormone to a human
CN101151048A (zh) *	2004-05-10	2008-03-26	纳斯泰克制药公司	增强甲状旁腺激素粘膜递送的组合物和方法
JP5007427B2 (ja)	2004-05-13	2012-08-22	アルザコーポレイション	副甲状腺ホルモン剤の経皮送達のための装置および方法
US7648965B2 (en)	2004-05-14	2010-01-19	Unigene Laboratories Inc.	Method for fostering bone formation and preservation
US20060069021A1 (en) *	2004-08-13	2006-03-30	Nastech Pharmaceutical Company Inc.	Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
WO2006073711A2 (en)	2005-01-06	2006-07-13	Kuros Biosurgery Ag	Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en)	2005-01-06	2013-11-05	Kuros Biosurgery Ag	Supplemented matrices for the repair of bone fractures
EP1879608A4 (en) *	2005-05-11	2009-11-11	Unigene Lab Inc	METHOD FOR STIMULATING BONE FORMATION AND PRESERVATION
US20070173447A1 (en) *	2005-10-25	2007-07-26	Nastech Pharmaceutical Company Inc.	Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
BRPI0618469A2 (pt) *	2005-11-10	2011-08-30	Univ Michigan Tech	hormÈnio paratiróide de urso preto e métodos de uso de hormÈnio paratiróide de urso preto
US20080051332A1 (en) *	2005-11-18	2008-02-28	Nastech Pharmaceutical Company Inc.	Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) *	2006-07-07	2008-05-22	Nastech Pharmaceutical Company Inc.	Pth formulations for intranasal delivery
EP1961765A1 (en) *	2006-12-08	2008-08-27	Zealand Pharma A/S	Truncated PTH peptides with a cyclic conformation
EP2136850B1 (en)	2007-04-13	2012-02-01	Kuros Biosurgery AG	Polymeric tissue sealant
US20110137243A1 (en) *	2007-09-06	2011-06-09	Abbott Cardiovascular Systems Inc.	Coating On A Balloon Device
EP2217260B1 (en) *	2007-12-04	2016-11-09	Ben-Gurion University Of The Negev Research And Development Authority	Amphiphilic peptide matrices for treatment of osteoporosis
JP2012512812A (ja)	2007-12-28	2012-06-07	クロス・バイオサージェリー・アクチェンゲゼルシャフト	フィブリンフォームに組込まれたｐｄｇｆ融合タンパク質
CN103893746A (zh) *	2009-09-09	2014-07-02	旭化成制药株式会社	含有pth的骨质疏松症治疗/预防剂
CA2782640A1 (en)	2009-12-07	2011-06-16	Michigan Technological University	Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9295663B2 (en)	2010-07-14	2016-03-29	Abbott Cardiovascular Systems Inc.	Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) *	2011-02-17	2012-08-23	帝人ファーマ株式会社	椎体骨折治療剤及びその評価方法
WO2012123028A1 (en)	2011-03-16	2012-09-20	Kuros Biosurgery Ag	Pharmaceutical formulation for use in spinal fusion
KR101787956B1 (ko)	2011-06-07	2017-10-18	아사히 가세이 파마 가부시키가이샤	고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법
US9700485B2 (en)	2013-04-24	2017-07-11	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP3411066B1 (en) *	2016-02-01	2026-05-13	Eli Lilly and Company	Parathyroid hormone anti-rankl antibody fusion compounds
WO2018144719A1 (en) *	2017-02-01	2018-08-09	The Johns Hopkins University	Parathyroid hormone and regeneration of degenerative discs disease
US20200289621A1 (en) *	2017-09-22	2020-09-17	Asahi Kasei Pharma Corporation	Teriparatide-containing liquid pharmaceutical composition having excellent stability
CA3101326C (en)	2018-10-29	2023-08-01	Asahi Kasei Pharma Corporation	Method for preventing or treating osteoporosis, characterized by administering teriparatide or salt thereof at a frequency of twice a week
EP4010360A1 (en)	2019-08-09	2022-06-15	Flagship Pioneering Innovations VI, LLC	Modulators of parathyroid hormone receptor (pthr1)
GB2590692A (en) *	2019-12-24	2021-07-07	Corthotec Ltd	Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4086196A (en)	1975-03-28	1978-04-25	Armour Pharmaceutical Company	Parathyroid hormone
IL78342A (en) *	1985-04-04	1991-06-10	Gen Hospital Corp	Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de)	1989-10-27	1991-05-08	Forssmann Wolf Georg	Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en)	1991-05-23	1993-05-04	Allelix Biopharmaceuticals Inc.	Essentially pure human parathyroid hormone
US5556940A (en)	1994-06-20	1996-09-17	National Research Council Of Canada	Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) *	1994-09-07	1996-03-19	Asahi Chem Ind Co Ltd	骨粗鬆症治療薬
JPH10511095A (ja) *	1994-12-19	1998-10-27	ベスイスラエルディーコネスメディカルセンターインコーポレイテッド	副甲状腺ホルモン又はその作動薬の低用量継続投与
US5747456A (en)	1994-12-19	1998-05-05	Beth Israel Deaconess Medical Center	Continuous low-dose administration of parathyroid hormone or its agonist
PT806945E (pt) *	1994-12-22	2003-09-30	Astrazeneca Ab	Preparacao terapeutica para inalacao que contem a hormona paratiroide, hpt
JPH08310965A (ja) *	1995-05-16	1996-11-26	Chugai Pharmaceut Co Ltd	骨癒合促進剤
CA2302255C (en) *	1997-09-09	2011-11-08	F. Hoffmann-La Roche Ag	Fracture healing using pthrp analogs
ZA9811127B (en)	1997-12-09	2000-07-11	Lilly Co Eli	Stabilized teriparatide solutions.
US20040033950A1 (en) *	2000-09-26	2004-02-19	Hock Janet M.	Method of increasing bone toughness and stiffness and reducing fractures
DZ2873A1 (fr) *	1998-08-19	2003-12-15	Lilly Co Eli	Procédé pour augmenter la dureté et la rigidité osseuse.
US6907597B1 (en)	2000-10-13	2005-06-14	Ati International Srl	Method and apparatus for constructing an executable program in memory
US6967759B2 (en)	2001-12-31	2005-11-22	Texas Instruments Incorporated	Pulse width modulation sequence generation
JP5796714B2 (ja)	2012-01-13	2015-10-21	株式会社リコー	定着装置及び画像形成装置
EP2949301B1 (en)	2014-05-27	2018-04-18	The Procter and Gamble Company	Absorbent core with curved and straight absorbent material areas

1999
- 1999-08-18 DZ DZ990173A patent/DZ2873A1/xx active
- 1999-08-18 AR ARP990104133A patent/AR033639A1/es unknown
- 1999-08-19 TR TR2000/03455T patent/TR200003455T2/xx unknown
- 1999-08-19 UA UA2000095457A patent/UA72205C2/uk unknown
- 1999-08-19 NZ NZ507056A patent/NZ507056A/en not_active IP Right Cessation
- 1999-08-19 CO CO99052525A patent/CO5130020A1/es unknown
- 1999-08-19 BR BR9909445-2A patent/BR9909445A/pt not_active Application Discontinuation
- 1999-08-19 ES ES15152726.4T patent/ES2549551T3/es not_active Expired - Lifetime
- 1999-08-19 PT PT101804474T patent/PT2266598T/pt unknown
- 1999-08-19 ES ES99942350T patent/ES2190244T3/es not_active Expired - Lifetime
- 1999-08-19 DK DK99942350T patent/DK1059933T3/da active
- 1999-08-19 EP EP15152726.4A patent/EP2907522B1/en not_active Revoked
- 1999-08-19 KR KR10-2001-7002092A patent/KR100454207B1/ko not_active Expired - Lifetime
- 1999-08-19 DK DK15152726.4T patent/DK2907522T3/da active
- 1999-08-19 PT PT06027055T patent/PT1769804E/pt unknown
- 1999-08-19 JP JP2000565916A patent/JP2002523375A/ja active Pending
- 1999-08-19 US US09/647,278 patent/US6977077B1/en not_active Expired - Lifetime
- 1999-08-19 EP EP99942350A patent/EP1059933B1/en not_active Revoked
- 1999-08-19 PL PL343595A patent/PL201688B1/pl not_active IP Right Cessation
- 1999-08-19 CA CA002325371A patent/CA2325371C/en not_active Expired - Lifetime
- 1999-08-19 ID IDW20010612A patent/ID29039A/id unknown
- 1999-08-19 IL IL13882999A patent/IL138829A0/xx unknown
- 1999-08-19 ES ES06027055T patent/ES2393200T3/es not_active Expired - Lifetime
- 1999-08-19 PE PE1999000839A patent/PE20001089A1/es not_active Application Discontinuation
- 1999-08-19 MY MYPI99003553A patent/MY129227A/en unknown
- 1999-08-19 ES ES10180447.4T patent/ES2621653T3/es not_active Expired - Lifetime
- 1999-08-19 PT PT99942350T patent/PT1059933E/pt unknown
- 1999-08-19 AT AT99942350T patent/ATE231000T1/de not_active IP Right Cessation
- 1999-08-19 HU HU0101594A patent/HU230697B1/hu unknown
- 1999-08-19 EA EA200001015A patent/EA003362B1/ru not_active IP Right Cessation
- 1999-08-19 EP EP10180447.4A patent/EP2266598B1/en not_active Expired - Lifetime
- 1999-08-19 AU AU55750/99A patent/AU746277B2/en not_active Expired
- 1999-08-19 CN CNB998083534A patent/CN1205997C/zh not_active Expired - Lifetime
- 1999-08-19 DK DK06027055.0T patent/DK1769804T3/da active
- 1999-08-19 WO PCT/US1999/018961 patent/WO2000010596A1/en not_active Ceased
- 1999-08-19 DE DE15152726.4T patent/DE15152726T1/de active Pending
- 1999-08-19 CZ CZ20004134A patent/CZ301017B6/cs not_active IP Right Cessation
- 1999-08-19 PT PT15152726T patent/PT2907522T/pt unknown
- 1999-08-19 HR HR20000755A patent/HRP20000755A2/hr not_active Application Discontinuation
- 1999-08-19 DK DK10180447.4T patent/DK2266598T3/da active
- 1999-08-19 HU HUP1200430 patent/HU1200430D0/hu not_active Application Discontinuation
- 1999-08-19 DE DE69904918T patent/DE69904918T2/de not_active Expired - Lifetime
- 1999-10-26 TW TW088114185A patent/TW576747B/zh not_active IP Right Cessation
2000
- 2000-10-03 IL IL138829A patent/IL138829A/en unknown
- 2000-11-24 NO NO20005947A patent/NO323984B1/no not_active IP Right Cessation
2005
- 2005-04-05 US US11/098,894 patent/US7163684B2/en not_active Expired - Lifetime
2007
- 2007-06-11 NO NO20072983A patent/NO20072983L/no not_active Application Discontinuation
2010
- 2010-10-29 JP JP2010244314A patent/JP2011021035A/ja not_active Withdrawn
2012
- 2012-11-14 CY CY20121101096T patent/CY1113343T1/el unknown
2014
- 2014-03-25 JP JP2014061763A patent/JP6177718B2/ja not_active Expired - Lifetime
- 2014-10-03 JP JP2014204577A patent/JP2015028065A/ja not_active Withdrawn
2017
- 2017-06-26 JP JP2017124301A patent/JP2017190332A/ja not_active Withdrawn
- 2017-10-13 CY CY20171101077T patent/CY1119552T1/el unknown

Also Published As

Publication number	Publication date
JP2011021035A (ja)	2011-02-03
EP1059933B1 (en)	2003-01-15
DZ2873A1 (fr)	2003-12-15
HUP0101594A3 (en)	2002-01-28
ES2549551T1 (es)	2015-10-29
IL138829A (en)	2011-01-31
IL138829A0 (en)	2001-10-31
HUP0101594A2 (hu)	2001-11-28
AU746277B2 (en)	2002-04-18
US7163684B2 (en)	2007-01-16
ES2549551T3 (es)	2017-11-27
CO5130020A1 (es)	2002-02-27
EP2266598A1 (en)	2010-12-29
PT2266598T (pt)	2017-05-02
ES2621653T3 (es)	2017-07-04
PL201688B1 (pl)	2009-04-30
JP2002523375A (ja)	2002-07-30
NO20005947D0 (no)	2000-11-24
AU5575099A (en)	2000-03-14
CA2325371C (en)	2004-08-17
DE69904918D1 (de)	2003-02-20
CZ301017B6 (cs)	2009-10-14
DK1059933T3 (da)	2003-04-07
PL343595A1 (en)	2001-08-27
CY1119552T1 (el)	2018-03-07
US6977077B1 (en)	2005-12-20
HRP20000755A2 (en)	2001-02-28
JP2015028065A (ja)	2015-02-12
DK1769804T3 (da)	2012-10-15
EA200001015A1 (ru)	2001-02-26
ES2393200T3 (es)	2012-12-19
JP6177718B2 (ja)	2017-08-09
HU1200430D0 (hu)	2001-11-28
TR200003455T2 (tr)	2001-06-21
NZ507056A (en)	2003-10-31
WO2000010596A1 (en)	2000-03-02
US20050197294A1 (en)	2005-09-08
HK1102496A1 (en)	2007-11-23
BR9909445A (pt)	2000-12-12
EP2266598B1 (en)	2017-02-22
ES2190244T3 (es)	2003-07-16
NO20005947L (no)	2000-11-24
JP2014139220A (ja)	2014-07-31
PT1059933E (pt)	2003-06-30
EP2907522B1 (en)	2017-08-02
PT2907522T (pt)	2017-10-23
JP2017190332A (ja)	2017-10-19
DK2907522T3 (da)	2017-10-23
HK1212602A1 (en)	2016-06-17
EP2907522A1 (en)	2015-08-19
DE15152726T1 (de)	2015-12-10
HK1030545A1 (en)	2001-05-11
TW576747B (en)	2004-02-21
CZ20004134A3 (cs)	2001-08-15
PT1769804E (pt)	2012-11-13
UA72205C2 (uk)	2005-02-15
CA2325371A1 (en)	2000-03-02
EA003362B1 (ru)	2003-04-24
CY1113343T1 (el)	2016-06-22
AR033639A1 (es)	2004-01-07
EP1059933A1 (en)	2000-12-20
DK2266598T3 (da)	2017-05-15
KR100454207B1 (ko)	2004-10-26
ID29039A (id)	2001-07-26
PE20001089A1 (es)	2000-11-04
MY129227A (en)	2007-03-30
CN1205997C (zh)	2005-06-15
KR20010072763A (ko)	2001-07-31
HU230697B1 (hu)	2017-09-28
ATE231000T1 (de)	2003-02-15
DK2907522T1 (da)	2015-10-19
CN1308545A (zh)	2001-08-15
DE69904918T2 (de)	2003-11-13
NO20072983L (no)	2000-11-24

Legal Events

Date	Code	Title	Description
2019-09-09	MK1K	Patent expired

Publication	Publication Date	Title
DK2907522T3 (da)	2017-10-23	Fremgangsmåde til øgning af knoglehårdhed og stivhed og reduktion af frakturer
US7351414B2 (en)	2008-04-01	Method of reducing the risk of bone fracture
EP1136076A1 (en)	2001-09-26	Method of increasing bone toughness and stiffness and reducing fractures
EP1769804B1 (en)	2012-09-19	hPTH(1-34) for use in preventing or reducing the incidence or severity of vertebral and / or non vertebral fracture in a male human
HK1037333A (en)	2002-02-08	Method of increasing bone toughness and stiffness and reducing fractures
HK1212602B (en)	2018-06-15	Method of increasing bone toughness and stiffness and reducing fractures
HK1102496B (en)	2013-08-02	Hpth(1-34) for use in preventing or reducing the incidence or severity of vertebral and / or non vertebral fracture in a male human
MXPA00009982A (en)	2001-07-31	Method of increasing bone toughness and stiffness and reducing fractures
HK1030545B (en)	2003-07-11	Use of parathyroide hormone consisting of aminoacid sequence 1-34 of human parathyroid hormone for reducing the risk of both vertebral and non vertebral bone fracture